Vatreptacog alfa
- Generic Name
- Vatreptacog alfa
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 897936-89-9
- Unique Ingredient Identifier
- 2F6ZF5WYCC
- Background
Vatreptacog Alfa (Activated) has been used in trials studying the treatment of Haemophilia B, Haemophilia A, Congenital Bleeding Disorder, Haemophilia A With Inhibitors, and Haemophilia B With Inhibitors.
- Associated Conditions
- -
- Associated Therapies
- -
Efficacy and Safety of NNC 0078-0000-0007 in Patients With Congenital Haemophilia and Inhibitors
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2011-07-12
- Last Posted Date
- 2017-05-15
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 72
- Registration Number
- NCT01392547
- Locations
- 🇵🇷
Novo Nordisk Clinical Trial Call Center, San Juan, Puerto Rico
Safety, Tolerability and Pharmacokinetics of NN1731 in Healthy Volunteers
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2009-01-14
- Last Posted Date
- 2015-01-05
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 32
- Registration Number
- NCT00822185
Haemophilia Patients With Inhibitors Being Treated for Acute Joint Bleeds
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-06-14
- Last Posted Date
- 2017-03-07
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 51
- Registration Number
- NCT00486278
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Manchester, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath